BG111090A - Контрацептивен процес и форми на приложение за същия - Google Patents

Контрацептивен процес и форми на приложение за същия

Info

Publication number
BG111090A
BG111090A BG10111090A BG11109011A BG111090A BG 111090 A BG111090 A BG 111090A BG 10111090 A BG10111090 A BG 10111090A BG 11109011 A BG11109011 A BG 11109011A BG 111090 A BG111090 A BG 111090A
Authority
BG
Bulgaria
Prior art keywords
administration
period
duration
phase
day
Prior art date
Application number
BG10111090A
Other languages
English (en)
Inventor
Hermann Kulmann
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of BG111090A publication Critical patent/BG111090A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Процес за хормонална контрацепция, при който в множество по същество неограничени по време свързани периоди на приемане и по избор продължаващи няколко години, и който във всеки случай включва най-малко един цикъл на приемане с продължителност константа - няколко дни за специфичния период на приемане и пауза на приемане с продължителност няколко дни, в която фазата или фазите на приемане на ден за приложение включва дневни единици с поне един хормон с контрацептивно действие, като естроген и/или гестаген, а в паузите на приемане или в паузите без приложение се приема или плацебо - свободни от хормони вещества, или по време на тази пауза не се приема нищо, и продължителността на фазата или фазите на приемане на поне крайния период на приемане е минимум 22 дни, характеризиращ се с това, чепродължителността на фазата или фазите на приемане при всеки период на приемане, предшестващ следващ период на приемане, е по-кратка спрямо продължителността на всеки следващ период на приемане, кактои форма на приложение на хормонална контрацепция, по-специално за изпълнението й.
BG10111090A 2000-09-14 2011-11-18 Контрацептивен процес и форми на приложение за същия BG111090A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10045380A DE10045380A1 (de) 2000-09-14 2000-09-14 Verfahren zur Kontrazeption und dessen Darreichungsform

Publications (1)

Publication Number Publication Date
BG111090A true BG111090A (bg) 2012-03-30

Family

ID=7656125

Family Applications (2)

Application Number Title Priority Date Filing Date
BG107625A BG107625A (bg) 2000-09-14 2003-03-11 Контрацептивен метод и форми за осъществяването му
BG10111090A BG111090A (bg) 2000-09-14 2011-11-18 Контрацептивен процес и форми на приложение за същия

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG107625A BG107625A (bg) 2000-09-14 2003-03-11 Контрацептивен метод и форми за осъществяването му

Country Status (32)

Country Link
US (2) US8076317B2 (bg)
EP (2) EP1317286B1 (bg)
JP (3) JP2004508398A (bg)
KR (3) KR20030031185A (bg)
CN (1) CN100560132C (bg)
AR (1) AR030737A1 (bg)
AT (1) ATE447972T1 (bg)
AU (2) AU8405201A (bg)
BG (2) BG107625A (bg)
BR (1) BR0113902A (bg)
CA (1) CA2420292C (bg)
CZ (1) CZ2003723A3 (bg)
DE (2) DE10045380A1 (bg)
EA (1) EA006875B1 (bg)
EE (1) EE200300103A (bg)
HK (1) HK1060305A1 (bg)
HR (1) HRP20030294A2 (bg)
HU (1) HUP0301042A3 (bg)
IL (2) IL154521A0 (bg)
ME (1) ME00291B (bg)
MX (1) MXPA03002070A (bg)
NO (1) NO20031152L (bg)
NZ (1) NZ524448A (bg)
PE (1) PE20020425A1 (bg)
PL (1) PL361161A1 (bg)
SK (1) SK3102003A3 (bg)
TW (1) TWI297271B (bg)
UA (1) UA93650C2 (bg)
UY (1) UY26932A1 (bg)
WO (1) WO2002022110A2 (bg)
YU (1) YU19003A (bg)
ZA (1) ZA200301359B (bg)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
AU2011226911B2 (en) * 2004-04-30 2014-06-19 Bayer Intellectual Property Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
GB0623813D0 (en) * 2006-11-29 2007-01-10 Stephenson Group Ltd Foam reduction
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
ES2218556T3 (es) * 1994-11-22 2004-11-16 Balance Pharmaceuticals, Inc. Metodos de contracepcion.
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
ATE271386T1 (de) 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Also Published As

Publication number Publication date
EP1317286B1 (en) 2009-11-11
YU19003A (sh) 2006-05-25
NO20031152D0 (no) 2003-03-13
ME00291B (me) 2011-05-10
EP2153849A2 (en) 2010-02-17
HUP0301042A2 (hu) 2003-10-28
US20120129823A1 (en) 2012-05-24
HUP0301042A3 (en) 2010-03-29
KR20090033502A (ko) 2009-04-03
CA2420292A1 (en) 2002-03-21
KR20100056577A (ko) 2010-05-27
JP2013241456A (ja) 2013-12-05
US8536156B2 (en) 2013-09-17
AU8405201A (en) 2002-03-26
JP2013006866A (ja) 2013-01-10
TWI297271B (en) 2008-06-01
US20040219174A1 (en) 2004-11-04
CN100560132C (zh) 2009-11-18
JP2004508398A (ja) 2004-03-18
CA2420292C (en) 2010-12-14
AR030737A1 (es) 2003-09-03
IL154521A (en) 2014-05-28
BG107625A (bg) 2003-11-28
CN1455681A (zh) 2003-11-12
SK3102003A3 (en) 2003-09-11
UY26932A1 (es) 2001-12-28
HK1060305A1 (en) 2004-08-06
KR20030031185A (ko) 2003-04-18
MXPA03002070A (es) 2003-06-24
BR0113902A (pt) 2003-07-22
WO2002022110A3 (en) 2002-07-04
US8076317B2 (en) 2011-12-13
NO20031152L (no) 2003-05-14
EE200300103A (et) 2005-02-15
EP2153849A3 (en) 2011-09-14
ATE447972T1 (de) 2009-11-15
EA200300338A1 (ru) 2003-08-28
PL361161A1 (en) 2004-09-20
WO2002022110A2 (en) 2002-03-21
EA006875B1 (ru) 2006-04-28
NZ524448A (en) 2005-03-24
DE60140462D1 (de) 2009-12-24
IL154521A0 (en) 2003-09-17
HRP20030294A2 (en) 2005-02-28
PE20020425A1 (es) 2002-06-15
EP1317286A2 (en) 2003-06-11
CZ2003723A3 (cs) 2003-06-18
KR101240232B1 (ko) 2013-03-07
DE10045380A1 (de) 2002-04-04
UA93650C2 (ru) 2011-03-10
ZA200301359B (en) 2004-02-05
AU2001284052B2 (en) 2006-11-30
MEP37608A (en) 2011-02-10

Similar Documents

Publication Publication Date Title
BG111090A (bg) Контрацептивен процес и форми на приложение за същия
NO986104D0 (no) Progesteron-anti-progesteron regimer
EA200201000A1 (ru) Гормон-заместительная терапия
NO982902L (no) FremgangsmÕte og preparatsett for Õ hindre befruktning hos hunn-pattedyr som omfatter en kombinasjon av gestagen og °strogen
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
DE59410116D1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
ATE11371T1 (de) Multistufen-kombinationssequentialpraeparate fuer die orale kontrazeption und verfahren zur kontrazeption.
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
DK1061929T3 (da) Farmaceutisk præparat på basis af syntetisk naturligt progesteron og östradiol samt fremgangsmåde til fremstilling deraf
TR200100234T2 (tr) Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.
DK1293210T3 (da) Midler og fremgangsmåde til hormonal prævention
CO5690602A2 (es) Regimenes anticonceptivos trifasicos extendidos
HUP9904049A2 (hu) Növekedési hormon komponens és csont antireszorpciós hatóanyag együttes felhasználása a csontritkulás ciklikus(koherens) kezelésében
DK0921804T3 (da) Tofase oral præventionsmetode og kit som indeholder en kombination af progestin og østrogen
IL118789A0 (en) Use of TNF receptor and steroid hormone for the preparation of pharmaceutical compositions
KR970705397A (ko) 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)
CAMPBELL et al. 10. Rapid Re-entrainment of the Estrous Cycle of Hamsters to Reversal of Scotophase and Photophase
RU97109898A (ru) Способ стимуляции остеоиндукции